Dr. Byrne LeeSurgical Oncologist
Dr. Byrne Lee is a renowned surgical oncologist who plays a major role in the multidisciplinary treatment of peritoneal mesothelioma at the Stanford Cancer Institute.
Get to Know Dr. Byrne Lee
Surgical oncologist Dr. Byrne Lee joined the Stanford Cancer Institute in 2019 to help build one of the nation’s premier peritoneal surface malignancy programs. He is well on his way.
One of Lee’s specialties is the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combination that has advanced treatment of mesothelioma cancer dramatically and given new hope to patients.
Lee was recruited to Stanford to be the inaugural director of the Regional Cancer Therapies program. The initiative, a first in Northern California, allows patients to benefit from a program focused on investigating and developing novel treatments previously underutilized.
Prior to coming to Stanford, Lee served as chief of mixed tumor services at City of Hope Comprehensive Cancer Center in Southern California. He is part of the Chicago Consensus Working Group, which authors guidelines designed to optimize the treatment of mesothelioma.
Lee has clinical expertise in several gastrointestinal malignancies, some of which utilize minimally invasive and robotic surgical techniques.
Specialties of Dr. Byrne Lee
- Peritoneal mesothelioma
- Liver cancer
- Appendiceal cancer
- Pancreatic cancer
- Stomach cancer
- Cytoreductive surgery
- Hyperthermic intraperitoneal chemotherapy
Dr. Byrne Lee’s Experience and Medical Education
- City of Hope Comprehensive Cancer Center
- St. Luke’s Hospital, Columbia University
- Stanford University (Clinical professor)
- City of Hope (Surgical oncology fellowship)
- Lenox Hill Hospital (General surgery residency)
- New York Medical College (M.D.)
Awards and Other Recognitions
- Top Doctors, Los Angeles magazine
- City of Hope Patient Safety Excellence Award
- Chicago Consensus Working Group (Collaborator)
Dr. Lee’s Specialty in HIPEC
Lee first learned the intricacies and vast benefits of hyperthermic intraperitoneal chemotherapy —known as the HIPEC procedure — during his fellowship at City of Hope Comprehensive Cancer Center in 2007. He has been utilizing it successfully ever since.
In combination with cytoreductive surgery, HIPEC has allowed select peritoneal mesothelioma patients to live a decade or more after treatment.
“I try not to use the word ‘cure,’ but we have something that works, and works really well,” he said. “We provide long-term survival.”
HIPEC is the intraperitoneal delivery of a heated chemotherapy solution, immediately after surgery, that is designed the kill any microscopic tumor cells in the abdomen that evaded the surgeon.
“When we first started using it, it was almost considered experimental,” Lee said. “It’s come a long way since then.”
Publications of Dr. Byrne Lee
- Chicago Consensus Working Group. (2020, April 13). The Chicago Consensus on peritoneal surface malignancies: Management of peritoneal mesothelioma. Cancer, ACS Journals.
- Konstantinidis, I. et al. (2019, September 6). Multivisceral Robotic Liver Surgery: Feasible and Safe. Journal of Robotic Surgery.
- Dumitra, S., Lee, B. (2019, January). ASO Author Reflections: A Novel Tool to Assess and Describe HIPEC Complications. ASO Author Reflections.
- Oliver, E. et al. (2018, September). Hypothermia Is Associated With Surgical Site Infection in Cytoreductive Surgery With Hyperthermic Intra-Peritoneal Chemotherapy. Surgical Infections.